Literature DB >> 16553934

Unseen Kala-azar deaths in south Sudan (1999-2002).

Simon M Collin1, Paul G Coleman, Koert Ritmeijer, Robert N Davidson.   

Abstract

OBJECTIVE: To estimate the number of deaths due to primary or relapse kala-azar (KA), which occurred unseen within the catchment area of Médecins Sans Frontières (MSF) clinics in southern Sudan.
METHOD: Review of clinical records of consecutive KA patients presenting between October 1998 and May 2002 in treatment centres at Wudier (Eastern Upper Nile), Lankien (Bieh State), Magang (Sobat Province) and Nimne and Thonyor (Western Upper Nile). To estimate the proportion of patients who either presented for treatment or died undetected, we compared the time-to-presentation of KA patients against the rate at which KA patients died before treatment becomes effective.
RESULTS: We estimated that the 2891 KA patients who presented at MSF clinics in south Sudan during the period October 1998 to May 2002 represented 55% (2891/5300; 95% CI 29%-77%) of the total number of cases of KA in that area and that 91% (2409/2649; 95% CI 78%-97%) of deaths from KA were undetected.
CONCLUSION: The huge proportion of undetected KA mortality is deeply troubling and unlikely to improve under prevailing political conditions.

Entities:  

Mesh:

Year:  2006        PMID: 16553934     DOI: 10.1111/j.1365-3156.2006.01589.x

Source DB:  PubMed          Journal:  Trop Med Int Health        ISSN: 1360-2276            Impact factor:   2.622


  16 in total

Review 1.  Recent Development of Visceral Leishmaniasis Treatments: Successes, Pitfalls, and Perspectives.

Authors:  Fabiana Alves; Graeme Bilbe; Séverine Blesson; Vishal Goyal; Séverine Monnerat; Charles Mowbray; Gina Muthoni Ouattara; Bernard Pécoul; Suman Rijal; Joelle Rode; Alexandra Solomos; Nathalie Strub-Wourgaft; Monique Wasunna; Susan Wells; Eduard E Zijlstra; Byron Arana; Jorge Alvar
Journal:  Clin Microbiol Rev       Date:  2018-08-29       Impact factor: 26.132

2.  Visceral leishmaniasis relapse in Southern Sudan (1999-2007): a retrospective study of risk factors and trends.

Authors:  Stanislaw Gorski; Simon M Collin; Koert Ritmeijer; Kees Keus; Francis Gatluak; Marius Mueller; Robert N Davidson
Journal:  PLoS Negl Trop Dis       Date:  2010-06-08

3.  Southern Sudan: an opportunity for NTD control and elimination?

Authors:  John Rumunu; Simon Brooker; Adrian Hopkins; Fasil Chane; Paul Emerson; Jan Kolaczinski
Journal:  Trends Parasitol       Date:  2009-06-17

4.  Metagenomic analysis of taxa associated with Lutzomyia longipalpis, vector of visceral leishmaniasis, using an unbiased high-throughput approach.

Authors:  Christina B McCarthy; Luis A Diambra; Rolando V Rivera Pomar
Journal:  PLoS Negl Trop Dis       Date:  2011-09-06

5.  Leishmaniasis worldwide and global estimates of its incidence.

Authors:  Jorge Alvar; Iván D Vélez; Caryn Bern; Mercé Herrero; Philippe Desjeux; Jorge Cano; Jean Jannin; Margriet den Boer
Journal:  PLoS One       Date:  2012-05-31       Impact factor: 3.240

6.  Kala-azar control, Uganda.

Authors:  Jan H Kolaczinski; Dagemlidet Tesfaye Worku; François Chappuis; Richard Reithinger; Narcis Kabatereine; Ambrose Onapa; Simon Brooker
Journal:  Emerg Infect Dis       Date:  2007-03       Impact factor: 6.883

7.  Developments in diagnosis and antileishmanial drugs.

Authors:  Prachi Bhargava; Rajni Singh
Journal:  Interdiscip Perspect Infect Dis       Date:  2012-10-18

8.  Kala-azar epidemiology and control, southern Sudan.

Authors:  Jan H Kolaczinski; Andrew Hope; Jose Antonio Ruiz; John Rumunu; Michaleen Richer; Jill Seaman
Journal:  Emerg Infect Dis       Date:  2008-04       Impact factor: 6.883

Review 9.  Visceral leishmaniasis in eastern Africa--current status.

Authors:  Richard Reithinger; Simon Brooker; Jan H Kolaczinski
Journal:  Trans R Soc Trop Med Hyg       Date:  2007-07-16       Impact factor: 2.184

Review 10.  Complexities of assessing the disease burden attributable to leishmaniasis.

Authors:  Caryn Bern; James H Maguire; Jorge Alvar
Journal:  PLoS Negl Trop Dis       Date:  2008-10-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.